Finance

ICE, CME Among Most Oversold Stocks; Rebound Ahead?

Intercontinental Exchange and CME Group landed on CNBC Pro’s list of the most oversold stocks after a volatile week, each posting a 14-day RSI of 24.4. The rout that hit tech and semiconductors pushed the S&P 500 down roughly 2% and the Nasdaq about 4.6% for the week, while the Dow managed a 0.6% gain.

ICE, CME Among Most Oversold Stocks; Rebound Ahead?

Key Takeaways

  • ICE and CME both registered a 14-day RSI of 24.4, qualifying them as heavily oversold on CNBC Pro’s screener.
  • CME shares fell about 10% for the week and ICE dropped more than 7%, marking outsized moves among market-infrastructure names.
  • The S&P 500 slipped nearly 2% and the Nasdaq dropped about 4.6% for the week, driven by tech and semiconductor weakness.
  • Other oversold names included Albemarle and Akamai Technologies, each with 14-day RSI readings below 24.
  • WTI fell 3.74% to $69.23 a barrel for the week, and several airlines showed overbought RSI readings, including Cardinal Health, Delta, United and Southwest.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Intercontinental Exchange (ICE)U.S. exchange operator flagged among the most oversold stocks
  • CME Group (CME)Derivatives exchange operator flagged among the most oversold stocks
  • Albemarle Corporation (ALB)Listed as an oversold name with a sub-24 RSI reading
  • Akamai Technologies (AKAM)Listed as an oversold name with a sub-24 RSI reading
  • Cardinal Health (CAH)Listed as overbought (RSI ~84.4)
  • Delta Air Lines (DAL)Listed as overbought (RSI ~76)
  • United Airlines (UAL)Listed as overbought (RSI 77.3)
  • Southwest Airlines (LUV)Listed as overbought (RSI 79.1)
  • KalshiStart-up exchange linked to a reported regulatory dispute over bitcoin perpetual futures
  • Commodity Futures Trading Commission (CFTC)U.S. derivatives regulator referenced in reports about a dispute with CME

MarketMoodz Analysis

A 14-day relative strength index (RSI) below 30 is a textbook signal that momentum has swung heavily against a stock; ICE and CME sitting at 24.4 puts them in that oversold territory. For traders and quant funds that use momentum or mean-reversion rules, that creates a potential entry point—especially for market-infrastructure names that typically trade on volumetric flows and derivatives activity rather than cyclical demand. The week’s broader backdrop—S&P down about 2% and Nasdaq off roughly 4.6%—shows this wasn’t isolated to exchanges but skewed toward technology and semiconductors, amplifying downside in correlated financial names.

Investors should treat the signal as a starting point, not a buy call. Oversold readings can persist in extended sell-offs, and exchanges face idiosyncratic risk here: reports of a dispute involving CME, the CFTC and Kalshi raise policy and competitive questions for derivatives businesses, though that report could not be independently verified in our review and warrants confirmation through filings or established reporting. Equally important are fundamentals—volume trends, fee revenues, open interest in futures and margin balances—because mean reversion in RSI won’t restore valuation if structural volumes decline.

Watch three things next week: trading volumes and open interest at ICE and CME, which drive revenue; macro cues—interest-rate trajectory and inflation—that affect volatility and derivatives demand; and oil price momentum after WTI closed near $69.23/bbl, a move that pressured transport and left several airlines on the overbought side technically. If volumes stabilize and macro risk eases, oversold technicals on ICE and CME could translate into a tactical rebound; if not, lower technicals may presage further downside and downgrades.

See the mood, every market morning

Get the Dip Buyer's Checklist — the 10 checks before you buy any dip — plus the free Morning Mood email: the market's fear/greed gauge and one name off the Oversold Board, before the open.

Get the free checklist + daily email

Want the whole Board? See the Dip Buyer's Edge →

This article is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.